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Microsomal epoxide hydrolase (mEH) is a bifunctional protein that plays a central role in carcinogen metabolism and is also able to
mediate the sodium-dependent uptake of bile acids into hepatocytes. Studies have identified a subject (S-1) with extremely elevated serum
bile salt levels in the absence of observable hepatocellular injury, suggesting a defect in bile acid uptake. In this individual, mEH protein and
mEH mRNA levels were reduced by approximately 95% and 85%, respectively, whereas the expression and amino acid sequence of another
bile acid transport protein (NTCP) was unaffected. Sequence analysis of the mEH gene (EPHX1) revealed a point mutation at an upstream
HNF-3 site (allele I) and in intron 1 (allele II), which resulted in a significant decrease in EPHX1 promoter activity in transient transfection
assays. Gel shift assays using a radiolabeled oligonucleotide from each region resulted in specific transcription factor binding patterns, which
were altered in the presence of the mutation. These studies demonstrate that the expression of mEH is greatly reduced in a patient with
hypercholanemia, suggesting that mEH participates in sodium-dependent bile acid uptake in human liver where its absence may contribute to
the etiology of this disease.D 2003 Elsevier Science B.V. All rights reserved.Keywords: Bile acid; Transport; m-epoxide hydrolase; Gene expression1. Introduction
The bifunctional protein, microsomal epoxide hydrolase
(mEH) (EC 3.3.2.3), plays a central role in the metabolism
of numerous xenobiotics such as polycyclic aromatic
hydrocarbon (PAH) carcinogens in the endoplasmic retic-
ulum [1] where it is expressed with a type I and type II
topological orientation [2]. We have previously demon-
strated that the type II form is targeted to the hepatocyte
plasma membrane [2] where mEH is capable of mediating
sodium-dependent uptake of bile acids [3–9] in parallel
with the sodium– taurocholate cotransporting protein
(NTCP) [10]. The contribution of multiple transporters to0925-4439/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
doi:10.1016/S0925-4439(03)00085-1
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E-mail address: dlevy@hsc.usc.edu (D. Levy).the sodium-dependent uptake of bile acids is supported by
the observations that in bile duct ligation induced extrahe-
patic cholestasis in rats where NTCP is undetectable,
significant sodium-dependent taurocholic acid transport
(30%) is still observed [11] in the presence of normal
mEH levels (unpublished observation). The possibility that
this residual uptake is mediated by mEH is supported by
previous studies using an anti-mEH antibody [9]. Signifi-
cant transport of taurocholate also occurs in the fch/fch
mouse. In this model of erythropoietic protoporphyria,
NTCP as well as a Na+-independent bile acid transporter,
OATP-1, were undetectable, yet 90% of intravenously
administered [3H]taurocholate was still transported into
the hepatic and biliary compartments [12], indicating an
alternative transport system.
To further explore the role of mEH in human bile acid
transport, studies have focused on a patient (S-1) who
exhibited serum bile salt levels that were elevated approx-ed.
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hepatocellular injury, as measured by biochemical and
histological parameters [13]. This clinical profile differs
from that observed in patients with progressive familial
intrahepatic cholestasis (PFIC-2) where a defect in bile acid
secretion, due to the loss of a bile salt efflux pump (Bsep)
[14], results in elevated intracellular bile acid levels and
considerable hepatocellular injury. The clinical profile
presented by S-1 suggests the presence of a defect in bile
acid uptake across the sinusoidal plasma membrane leading
to elevated serum levels. Since NTCP mRNA and protein
expression levels in S-1 were quantitatively normal with no
defects in the deduced amino acid sequence [13], a goal of
the present study was to characterize the expression of
mEH. This analysis indicated that both mEH protein and
mEH mRNA levels were substantially reduced, suggesting
a specific defect in the promoter of the mEH gene
(EPHX1) regulating mEH expression in human liver.
Sequence analysis of EPHX1 from S-1 detected a point
mutation in an upstream HNF-3 site (allele I) and in intron
1 (allele II) which significantly decreased EPHX1 promoter
activity and altered transcription factor binding at these
sites. These results demonstrate that these two allelic sites
are involved in the regulation of EPHX1 expression and
suggest that mEH may play a significant role in sodium-
dependent bile acid uptake in human liver where its
decreased expression may contribute to the etiology of
hypercholanemia.2. Materials and methods
2.1. Western blot analysis
Microsome preparations of liver biopsy specimens from
S-1 and a normal subject were made as described [13].
Samples (2 Ag) were separated on a 10% SDS-PAGE and
subjected to Western analysis using a polyclonal antibody
against mEH and the ProtoBlot alkaline phosphatase detec-
tion system (Promega, Madison, WI).
2.2. Northern blot analysis
Total RNA from biopsy samples from S-1 and a normal
individual were isolated and blotted as previously described
[13]. A 351 bp EcoRI (cDNA nt 808)/EcoRI (1159)
fragment was isolated from a human mEH cDNA prepared
by RT-PCR. This fragment, containing 67 bp of exon 5, 208
bp of exon 6, and 76 bp of exon 7, was used to detect the
mEH message. This probe was radiolabeled using the
random hexamer method. Hybridization and high stringency
washes were performed according to manufacturer’s instruc-
tions (New England Nuclear, Boston, MA). The blot was
scanned using a phosphoimager (Molecular Dynamics,
Sunnyvale, CA) and exposed to X-ray film with an inten-
sifying screen at  70 jC.2.3. Cloning and sequencing of EPHX1
Genomic DNA was isolated from lymphocytes from S-
1 and the patient’s father using a Puregene DNA isolation
kit (Gentra, Minneapolis, MN) using instructions supplied
by the manufacturer. The sequences from  2017 (the
first nucleotide of exon 1 defined as + 1) to 3619,
including 2017 bp 5Vflanking sequence, exon 1 (270
bp), intron 1 (3182 bp), the 5V167 bp of exon 2 were
determined by sequencing [15] the overlapping DNA
fragments produced by PCR using primers based on the
EPHX1 gene sequence [16]. The genomic sequences more
than 2 kb upstream from exon 1 were not included in the
published EPHX1 gene sequence [16]. In order to clone
and analyze these sequences, we obtained a P1 clone from
Genomic Systems Inc. (St. Louis, MO), that contained the
EPHX1 gene. The P1 clone was digested with HindIII
and shotgun-ligated into PUC18. The HindIII clone con-
taining the sequences upstream of  2 kb was selected by
restriction enzyme mapping for the 182 bp ScaI ( 1979)/
HindIII ( 1797) fragment followed by confirmation by
DNA sequencing. Based on the P1 sequence, the
corresponding sequences up to  4391 in S-1 and the
father were determined.
2.4. Preparation of reporter gene constructs
To test the effect of the polymorphic forms in the 2 kb 5V
sequences, three different 1.3 kb StuI( 1298)/MfeI(21)
promoter fragments representing alleles I, II and III (wild-
type) were cloned into the promoterless expression vector
pOGH (Nichols Institute Diagnostics, San Juan Capistrano,
CA) which contained a human growth hormone (hGH)
reporter gene. To prepare the 1.3 kb constructs, a 1.3 kb
StuI/MfeI fragment was isolated from the  1528/310
fragment and reinserted into pBSK digested with EcoRV
and EcoR1. The insert was then excised as a HindIII/
BamH1 fragment and cloned into the pOGH construct. To
examine the effect of sequence variations upstream from the
2 kb 5V-flanking region, a SstI( 4386)/MfeI(21) fragment
for each allele was used. To make these constructs, BamHI
(in primer)/HindIII( 1797) fragments were isolated from
the  4391/ 967 PCR fragment and cloned into pBSK.
The inserts were then isolated as XbaI(linker)/HindIII frag-
ments and ligated to the HindIII( 1797)/MfeI(21) frag-
ments of the corresponding alleles and the vector pOGH in
which a XbaI site was added to the 5Vend of the original
linker HindIII site. To examine the effect of the heterozy-
gous sequence variations in intron 1 on the promoter
activity, three different 5255 bp DNA fragments represent-
ing alleles I, II and III were inserted into the pOGH vector,
including the 1797 bp 5V sequence (from the HindIII site at
 1797), exon 1 (270 bp), entire intron 1 (3182 bp) and the
first 6 bp of exon 2, including the nucleotide A of the
translation initiation codon ATG (3458–3460). The 5255 bp
DNA inserts for each allele were formed by ligation of four
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BglII( 1397) isolated from the  2017/ 1387 fragment,
BglII( 1397)/MfeI(21) isolated from the  1528/310 frag-
ment, MfeI(21)/XbaI(2065) isolated from the  111/2331
fragment, and XbaI(2065)/3458 produced from the 1959/
3619 fragment by PCR using the primer pair 5V-
ATCAAGCTTCTTGG-GTTTCCAAGACAGAGCGAG-
3V(5Vprimer) and 5V-ATCGGATCCTGGCTCCTGCAAGAT-
GAGGGGAAG-3V(3Vprimer containing a BamHI site). The
resulting 5255 bp HindIII/BamHI fragments were inserted
into the pOGH vector.
2.5. Promoter activity assay
HepG2 and COS-7 cells were obtained from the Amer-
ican Type Culture Collection (ATCC) and grown at 37 jC in
Dulbecco’s modified Eagle’s medium supplemented with
10% of fetal bovine serum. The pOGH constructs were
transiently transfected into HepG2 cells using the DEAE-
Dextran transfection method [17]. Three micrograms of
pSV-beta-galactosidase control vector (Promega) were in-
cluded in each transfection as an internal control of trans-
fection efficiency. The hGH produced was excreted into the
medium and measured by a radioimmunoassay (Nichols
Institute Diagnostics). Construct pXGH5, which contained
the mouse metallothionein promoter, was used as a positive
control to monitor transfection efficiency in each cell line. A
promoterless construct was used as a negative control. The
experiments (n = 3–4) were carried out in triplicate on 100
mm dishes and the results were normalized to h-galactosi-
dase values after subtracting the background of the negative
control. The data represent the meansF S.E. Each separate
experiment was repeated with freshly prepared plasmid
preparations to eliminate the effect of DNA purity of each
construct. Identical procedures were carried out using COS-
7 cells.
2.6. Electrophoretic mobility shift assay (EMSA)
Nuclear proteins were extracted from cultured HepG2
cells as previously reported [18]. HeLa nuclear extracts
were purchased from Promega. Sense and antisense oligo-
nucleotides containing the mutation sites were synthesized,
annealed and radiolabeled with 32P-dNTP in fill-in reac-
tions with Klenow large fragment of DNA polymerase I.
Two pairs of oligonucleotides were used to study the
mutation site in intron 1 at nt 2557 on allele II. Only the
sequence of sense oligonucleotides after fill-in reaction are
shown below, with the nucleotides added during the fill-in
reaction in parenthesis and the mutated nucleotides under-
lined. Sense strand for wild-type (WT); 5V-CATGGCTCT-
TACACAGCTAAGCTGTGTGGC(CATG)-3V; C>G2557
( M ) ; 5 V- C AT G G C T C T TA C A C AG C TAAGG
TGTGTGGC(CATG)-3V. Three pairs of oligonucleotides
were used to study the mutation site at nt  4238. Two
pairs contained the HNF-3 site on allele I. Sense strand forwild-type; 5V-ATCTCTTATTTACTTTAAAAAA(CACT)-
3V; mutation at  4238T>A; 5V-ATCTCTTATTTACTTA
AAAAAA(CACT)-3V. Oligonucleotides containing a con-
sensus HNF-3 binding site [19] were also synthesized. The
sense strand was 5V-AAAGAGATTATTTGCTTATTG
(CATCGA)-3V; 1.25 Ag of poly[dI–dC].poly[dI–dC] (Sig-
ma, St. Louis, MO) was preincubated with 5 Ag of nuclear
proteins for 10 min at room temperature in a mix of 19
Al containing 20 mM Tris–HCl, pH 7.8, 1 mM MgCl2, 50
mM NaCl, 0.5 mM EDTA, 0.5 mM DTT and 10%
glycerol. Radiolabeled oligonucleotides (0.5 Al) (about 10
fmol and 10,000 cpm) were added and the incubation was
continued for another 20 min at room temperature. After
mixing with 2.5 Al of loading buffer (250 mM Tris–HCl,
pH 7.8, 0.2% bromophenyl blue, 40% glycerol), the
mixture was loaded on a 6% nondenaturing acrylamide
(acrylamide:bisacrylamide = 29:1) in 0.5Tris–borate/
EDTA electrophoresis buffer prerun at 50 V for 1 h. Gel
electrophoresis was carried out at 150 V (about 10 V/cm)
for 1.5 h. The bands were visualized by autoradiography.
To further characterize the factor binding to the allele I site,
antibodies against HNF-3a, h and g were incubated with
the HepG2 nuclear extract for 2 h on ice before adding the
radiolabeled probe. EMSA was then performed as de-
scribed above.
2.7. Genotyping with allele-specific PCR
In order to estimate the allele frequency of the
 4238T>A mutation at the upstream HNF-3 site and the
2557C>G mutation in intron 1, semi-nested allele-specific
PCR was performed as previously described [20] but with
primers specific to both alleles which differ only at the last
(3V) nucleotide.
2.8. Human subjects
Informed consent in writing was obtained from each
subject and the study protocol conformed to the ethical
guidelines of the 1975 Declaration of Helsinki as reflected
in a priori approval by the appropriate institutional review
committee.3. Results
3.1. Western blot analysis of mEH expression
Western blot analyses of mEH expression were per-
formed with microsome preparations from a liver biopsy
sample obtained from S-1 and two normal subjects. As
shown in Fig. 1, the level of mEH expression in the patient
(S-1) was reduced to less than 5% of the levels observed in
normal liver samples, suggesting that the greatly decreased
levels of mEH may contribute to the observed elevated
serum bile salt levels.
Fig. 1. Analysis of mEH expression in the liver of S-1 and two control
individuals. Two micrograms of the microsome preparation from liver
biopsy samples were analyzed by SDS-PAGE and immunoblotted with a
polyclonal antibody against mEH and the ProtoBlot alkaline phosphatase
detection system (Promega). Fig. 3. The strategy for cloning and sequencing EPHX1 genomic
sequences. The scale on the top shows base pair numbers of the EPHX1
gene. The sequences upstream of the transcription initiation site are shown
in negative numbers. The EPHX1 gene is represented by a thick line and
exons 1, 2, represented by closed boxes. The horizontal arrows represent
PCR primers. The thin lines below are PCR products. Vertical arrows
indicate the location of allele I ( 4238T>A) and II (2557C>G) mutations
shown in Table 1.
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Northern blot analyses on total mRNAwere performed to
establish whether the low level of mEH expression observed
in the patient’s (S-1) liver was associated with reduced mEH
mRNA levels. A DNA probe containing exon 6 and part of
exons 5 and 7 were isolated for Northern blot analysis. As
shown in Fig. 2, the mEH mRNA level was decreased to
approximately 15% of normal levels suggesting that the low
mEH levels observed in S-1 may result from a defect in the
transcription of EPHX1.
3.3. Sequencing of the 5V flanking region and intron 1 of
EPHX1
Sequence analysis was carried out in an effort to char-
acterize possible polymorphisms that could inhibit EPHX1
transcriptional activity resulting in the low levels of mEH
mRNA. The strategies for cloning the genomic sequences
are shown in Fig. 3. In the first 2 kb of the 5V region, five
heterozygous sequence variations were observed in allele I
from S-1 and the patient’s father, and allele II from S-1Fig. 2. Northern analysis of mEH mRNA levels in the liver of S-1 and a
control individual. Ten micrograms of total RNA isolated from liver biopsy
samples were hybridized with a cDNA probe containing exons 5, 6, and 7
(a). Panel (b) shows the same blot probed by an actin cDNA probe to
normalize the intensities of the mEH signals.when compared with the wild-type sequence (N) as shown
in Table 1: (a) an A insertion at  1060, and a  718C>A
substitution in allele I of S-1 and the father; (b) three
substitutions ( 200T>C,  259T>C and  290G>T) in
allele II in S-1. The sequence upstream from  2 kb was not
available and was thus obtained using a P1 clone with an
approximately 100-kb insert containing EPHX1. A HindIII/
HindIII P1 fragment containing the region immediately
upstream from the 5V end of the published sequence [16]
was selected by restriction enzyme mapping, sequenced and
designated as N (Table 1). The corresponding sequences
from the patient and the father were cloned by PCR and
compared with the P1 sequence. Allele I of the patient’s
DNA in this region was determined by the A insertion at
 1060, which was included in the PCR product ( 4391/Table 1
Sequence variation in EPHX1 in the 5Vupstream and intron regions in the
subject (S-1) and father (F/S-1)
N denotes wild-type sequences obtained from a P1 clone (Materials and
methods) (lines 1 to 4) and [16] (lines 5 to 12). The sequences differing
from N are in boldface. The numbers in parentheses are the corresponding
positions in GenBank sequences AC058768. A dash (– ) in N denotes an
insertion at that position and a dash in S-1 and the F/S-1 denotes a deletion.
The two sequence variations which affect promoter activity are boxed.
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patient’s DNA as allele II. No sequence variations were
detected in allele II compared with the control sequence (N),
however, a  4238T>A at a putative HNF-3 site [19] and a
AAC deletion at  2322, 2323 and  2324 were detected
in allele I (Table 1). Sequencing of the 3179 bp intron 1 of
EPHX1 indicated the presence of three heterozygous sub-
stitutions in S-1 and the father, namely, a 880 T>C and 2140
G>A on allele I of both subjects and a 2557 C>G substi-
tution on allele II of S-1.
3.4. Promoter activity measurements
To test the effects of the sequence polymorphisms
observed in the 4 kb 5V flanking region and in intron 1 of
EPHX1 on promoter activity, fragments from these regions,
representing alleles I, II and III, were linked to the hGH
reporter gene in the expression vector pOGH and transiently
transfected into HepG2 cells in which endogenous mEH
expression could be detected by Western analysis. The five
heterozygous sequence polymorphisms in the  200 to
 1060 bp region (Table 1) had no effect on EPHX1
promoter activity (Fig. 4C). In contrast, reporter constructs
using allele I, which included the AAC deletion
( 2322, 2323, 2324) and the  4238T>A substitution
demonstrated a significant decrease in promoter activityFig. 4. The effect of the sequence variations in the 5Vflanking region of S-1 on EPH
were transiently transfected into HepG2 cells and the released hGH measured by
fragments used in the promoter activity assay in B (4.4 kb SstI/MfeI) and C (1.3 kb
gene with corresponding sequence variations. The activity measured is expressed
evaluate only the effect of the  4238T>A mutation in allele I. (C) The three co(Fig. 4B). This effect could be obtained utilizing a construct
that contained only the  4238T>A mutation.
Analysis of intron 1 polymorphisms demonstrated that
two of the heterozygous substitutions on allele I 880 T>C
and 2140G>A had no effect on promoter activity (Fig. 5B);
however, the 2557 C>G substitution in allele II significantly
suppressed activity by approximately 86%. A similar result
was also obtained in the absence of the other 5V poly-
morphisms (Fig. 5B). Transfection of the wild-type intron 1
and the 5V upstream constructs into COS-7 cells did not
result in measurable promoter activity (data not shown),
suggesting that the observed EPHX1 promoter activity in
HepG2 cells may be liver-specific. These results therefore
demonstrate that a mutation in each allele of EPHX1 in S-1
leads to a significant decrease in promoter activity, suggest-
ing that these mutations may affect mEH expression in the
hepatocytes of S-1.
3.5. Electrophoretic mobility shift assay
EMSA analysis was employed to evaluate the effect of
the two mutations (2557C>G, 4238T>A) in alleles II
and I, which significantly inhibit EPHX1 promoter activ-
ity, on the nuclear protein binding patterns at putative
transcription factor binding sites. EMSA analysis using a
radiolabeled wild-type oligonucleotide (2540–2569 bp)X1 promoter activity. Six pOGH constructs representing alleles I, II and III
a radioimmunoassay. (A) Sequence variations in each allele and the DNA
StuI/MfeI). (B) DNA fragments of each allele connected to the hGH reporter
as the percentage of the wild-type (allele III). A I/III construct was used to
nstructs were analyzed for promoter activity as described in B.
Fig. 5. The effect of sequence variations in intron 1 of S-1 on EPHX1 promoter activity. Four pOGH constructs were analyzed as describe in Fig. 4. (A) DNA
region (HindIII/A of ATG in exon 2) to be used in the promoter activity assay, with the sequence variations in allele I and II indicated. (B) DNA fragments of
each allele were connected to the hGH reporter gene. A III/II constructs was also made in which the 5Vflanking sequence of the allele II was replaced by that of
the allele III (wild-type) so the effect of the 2557C>G mutation in allele II could be examined alone. Analysis of promoter activity was carried out as described
in Fig. 4.
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formation of one band (Fig. 6, lane 1). This binding could
be inhibited in a concentration-dependent fashion with an
excess (10–100 ) of unlabeled probe demonstrating the
specificity of the interaction (lanes 2–4). Competition
with the unlabeled probe containing the 2557C>G muta-
tion, however, had no effect on the binding (lane 5).
EMSA analysis with the mutant oligonucleotide resulted
in the total loss of the labeled band observed with the WT
probe (lane 6). The small amount of binding was shown
to be non-specific as it was unaffected by unlabeled probe
(lane 7).Fig. 6. Characterization of nuclear protein binding to the intron 1 region
containing the allele II 2557C>G mutation site by EMSA. Radiolabeled
oligonucleotides (10,000 cpm) containing the wild-type (WT) and mutant
(M) sequences (Materials and methods) were used as probes in EMSA
using HepG2 nuclear extracts (5 Ag). A 10- to 100-fold excess of unlabeled
oligonucleotide was used as competitive DNA. Nuclear proteins bound to
the WT oligonucleotide in the absence (lane 1) or presence (lane 2–4) of
unlabeled WT oligonucleotide or M oligonucleotide (lane 5). Nuclear
proteins labeled with the oligonucleotide containing the naturally occurring
2557C>G mutation (M) in the absence (lane 6) or presence (lane 7) of 100-
fold excess of unlabeled oligonucleotide (M).Examination of the region surrounding the  4238T>A
upstream mutation on allele I indicated the presence of a
consensus HNF-3 binding site [19]. EMSA analysis with the
radiolabeled wild-type probe produced two protein–DNA
species (A,B) (Fig. 7, lane 1). The specificity of this
interaction was demonstrated by competition with unlabeled
probe (lane 2). Competition with an HNF-3 oligonucleotide
also inhibited the formation of bands A and B (lane 3).
EMSA analysis using the probe containing the  4238T>A
mutation (M) resulted in a substantial specific increase in
the intensity of bands A and B (lane 5). This binding was
shown, as in the wild-type case, to be specific since it could
be eliminated by competition with unlabeled probe (lane 6)
or with an HNF-3 oligonucleotide (lane 7). To further
establish the presence of HNF-3 in the protein–DNA
complex, anti HNF-3 antibodies were incorporated intoFig. 7. Characterization of nuclear protein binding to the 5V upstream
region containing the allele I  4238T>A mutation site by EMSA.
Radiolabeled oligonucleotides (10,000 cpm) containing the WT and M
sequences (Materials and methods) were used as probes in EMSA as
described in Fig. 6. Nuclear proteins bound to the WT oligonucleotide
alone (lane 1) and in the presence of 50-fold excess of unlabeled WT
oligonucleotide (lane 2), HNF-3 (lane 3) or HNF-3h antibody (Ab) (lane
4). Nuclear proteins bound to the oligonucleotide containing the
 4238T>A mutation (M) (lane 5) and in the presence of a 50-fold
excess of unlabeled oligonucleotide (M) (lane 6), HNF-3 (lane 7) or HNF-
3h antibody (lane 8).
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added to the nuclear extract reaction, a substantial reduction
in the intensity of band A was observed for both the wild-
type and mutant forms (lanes 4, 8). No change in the
binding was observed when anti-HNF-3a or g antibodies
were used (data not shown). The decrease in band A
intensity using the WT and M probes suggests specific
binding of HNF-3h to the added antibody. The absence of
an observable supershifted band suggests that the resulting
complex now binds very weakly to the labeled oligonucle-
otide as previously reported [21].The complexes shown in
Figs. 6 and 7 were not observed when HeLa nuclear extracts
were used (data not shown). The EMSA analysis thus
supports the thesis that the mutations in the HNF-3 region
of allele I and in intron 1 of allele II can affect EPHX1
promoter activity by altering the binding characteristics of
transcription factors that bind in these two regions.
3.6. Genotyping with allele-specific PCR
Allele-specific PCR was performed to determine the
frequency of occurrence of the EPHX1 mutation described
above in the general population composed of Caucasians,
African–Americans, Latinos and Asians [22]. Serum bile
acid concentration values are not available. The  4238T>A
mutation in allele I was found as a heterozygous change
in 0.7% of the subjects (n = 270). The 2557C>G mutation
in allele II was found as a heterozygous change in 16%
and as a homozygous change in 1.6% of the subjects
(n = 509).4. Discussion
In this study, we have established that the expression of
the bile acid transporter, mEH, is greatly reduced in a human
subject (S-1) who exhibits highly elevated serum bile acid
levels (hypercholanemia) in the absence of cholestatic
parameters, possibly resulting from an apparent reduced
bile acid uptake capacity. Northern blot analysis demon-
strated that mEH mRNA was greatly decreased, suggesting
the presence of a mutation(s) that affected EPHX1 promoter
activity. Sequence analysis of the 4.4 kb 5Vupstream and
3.2 kb intron 1 regions elucidated a number of polymor-
phisms (Table 1) whose effect on EPHX1 promoter activity
were evaluated using a transient expression assay in HepG2
cells. A  4238T>A substitution in the 5Vupstream region
in allele I at a putative HNF-3 site and a 2557C>G
substitution in intron 1 of allele II both significantly de-
creased EHPX1 promoter activity (Figs. 4 and 5). The 86%
decrease in promoter activity resulting from the intron 1
mutation is consistent with the approximately 85% decrease
in mEH mRNA. The 53% decrease resulting from the
 4238T>A mutation, however, may be an underestimate
of the actual effect in human hepatocytes since additional
regulatory cis-elements may be missing from the constructsused in this analysis and transcription factor levels found in
HepG2 cells may be different from those found in hepato-
cytes. Many promoters have tissue-specific regulatory ele-
ments located far upstream from the transcription initiation
site and/or in introns, where mutations or deletions result in
significant alterations in promoter activity [23–25] as de-
scribed herein for EPHX1. The existence of both defective
alleles appears necessary for the expression of the observed
hypercholanemia since the father of S-1, who only pos-
sessed the functional mutation in the HNF-3 region, had
normal serum glycocholate levels.
EMSA were performed with HepG2 nuclear extracts to
determine transcription factor-binding elements in the mu-
tated regions of allele I and allele II. Specific binding of
nuclear proteins was detected at both sites, which was
significantly altered as a result of the observed mutations,
suggesting that these sites are important regulatory regions in
EPHX1 whose alteration results in significant decreases in
EPHX1 promoter activity. The presence of the  4238T>A
mutation resulted in a large increase in HNF-3h binding
(Fig. 7). These results suggest that binding of this factor
could act as a repressor of EPHX1 expression, an effect
further increased as a result of the mutation. HNF-3h has
also been shown to negatively regulate glucagon gene
expression [26]. HFN-3 is a member of the winged helix
family of transcription factors and plays a critical role in
liver-specific expression of many genes by binding to the
promoter region [27]. The presence of the 2557C>G muta-
tion in intron 1, in contrast, resulted in the loss of binding of,
as yet, an uncharacterized factor (Fig. 6, lane 6) suggesting
that this protein plays a significant role in EPHX1 transcrip-
tion. Although the sequence in this region is similar to an
AP-4 site, the intron 1 probe was unable to bind any factors
in HeLa nuclear extract although it contained ample AP-4 as
evidenced by the binding to the authentic AP-4 oligonucleo-
tides (data not shown). The identity of the factor(s) binding
to this region is under investigation.
The concentration of bile acids in the blood is regulated
by the coordinated activity of the transport systems for these
substrates in hepatocytes and ileal enterocytes [28]. Several
cholestatic disorders have been associated with alterations in
hepatocellular transport systems in the canalicular mem-
brane such as progressive familial intrahepatic cholestasis
Type 1 [29], Type 2 [14], Type 3 [30], and benign recurrent
intrahepatic cholestasis [29] where liver marker enzymes are
highly elevated accompanied by significant morphological
alterations indicating hepatocellular injury. The report [13]
of a patient with highly elevated levels of bile acids in the
blood with no significant hepatocellular injury suggests that
this disease, in contrast to the above cholestatic disorders,
may result from a defect in bile acid uptake across the
sinusoidal membrane. While the expression levels and
amino acid sequence of the sodium-dependent bile acid
uptake protein NTCP were normal in this subject (S-1), the
level of mEH expressed in the liver was reduced by
approximately 95%, suggesting a significant role for mEH
Q. Zhu et al. / Biochimica et Biophysica Acta 1638 (2003) 208–216 215in the etiology of the syndrome observed in this patient and
in bile acid transport in human liver. The normal levels of
NTCP in S-1 are in contrast to the observation in a rat model
of cholestasis secondary to common bile duct ligation [11]
and in biliary atresia patients [13] where extensive down-
regulation of NTCP and NTCP mRNA were observed in
cases where intrahepatocyte bile acid levels are significantly
elevated. The failure to observe NTCP down-regulation in
S-1 suggests that intracellular bile acid levels are not
elevated, and supports the proposal that the observed hyper-
cholanemia results from an uptake rather than an efflux
defect.
This conclusion is further supported utilizing the mEH
knockout mouse [31]. In our studies, analysis of the serum
by electrospray tandem mass spectrometry indicated that the
concentration of several serum bile acids were substantially
increased. This observation is consistent with the bile acid
transport properties of mEH previously reported [3–9]. In
addition, the expression of several other genes involved in
the synthesis and transport of bile acids were also shown to
be significantly altered. The results of these studies, which
will be described in a subsequent report, strongly suggest a
role of mEH in bile acid homeostasis. In this regard, it
should also be noted that feeding mice a diet supplemented
with 1% cholic acid resulted in a 4-fold increase in the
expression of mEH mRNA [32].
The contributions of mEH and NTCP to bile acid
transport in humans depends on the substrate specificities
of these two transport proteins. While NTCP is able to
transport taurocholate, its ability to transport glycocholate is
significantly reduced, with levels ranging from 30% of
taurocholate values in transfected CHO cells [33] to 14%
in transfected COS-7 cells (unpublished observation). In
contrast, mEH expressed in MDCK cells was shown to
transport glycocholate at a rate 2.5 times greater than that
observed for taurocholate uptake (unpublished observation).
Because glyco-conjugation is the major form of bile acid in
humans [34–36], the above results suggest that mEH may
be responsible for a significant percentage of bile acid
uptake in human liver such that the loss of mEH in this
patient (S-1), despite normal NTCP expression, appears to
result in a significant decrease in net bile acid uptake
resulting in elevated serum bile acid levels. The severity
of this hypercholanemic syndrome should therefore also
depend on the bile acid conjugation profile of a subject
expressing these mutations where a higher percentage of
tauro-conjugation could attenuate the elevated serum bile
acid levels as they would be efficiently transported by
NTCP. The co-expression of two functionally distinct he-
patocyte sodium-dependent bile acid transport systems in
humans is also supported by the differential inhibition of
taurocholate and glycocholate by cyclosporin A [37].
The central role of mEH in the metabolism of numerous
carcinogens suggests that variations in mEH levels and/or
effective activity could have a profound effect on the
susceptibility to various forms of cancer. This hypothesisis supported by our recent study that demonstrates an
association between several polymorphic forms of EPHX1
including the intron 1 mutation described in this report and
susceptibility to colorectal adenomas [22], an observation
further supporting the effect of the 2557C>G mutation on
the expression levels of mEH. The role of mEH in the
metabolic activation of polycyclic aromatic hydrocarbon
carcinogens has also been established utilizing the mEH
knockout mouse [31].
In conclusion, these studies have demonstrated that two
point mutations in regulatory regions of EPHX1, found in a
patient with highly elevated serum bile acids (hyperchola-
nemia) result in an extensive reduction in gene expression
associated with a large increase in factor binding at an HNF-
3 site in allele I and the loss of factor binding at the intron 1
site in allele II. These DNA alterations are associated with
an apparent decrease in bile acid transport capacity, which in
turn decreases intracellular bile acids which play a critical
role in cholesterol homeostasis in addition to numerous
physiological processes. Further analysis of the factors that
bind to the intron 1 region, the 5V-upstream region as well as
the basal promoter is in progress, in order to elucidate the
mechanism of EPHX1 regulation. The transport character-
istic of mEH and NTCP in relation to the bile acid
conjugation profiles in humans as well as the results of this
study suggest that mEH may play a significant role in
human hepatocyte bile acid uptake and in the cause of the
observed hypercholanemia.Acknowledgements
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